Overview
- 15 inspections across 14 sites are on record.
- 21 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-12-12.
At a glance
Inspections
15
Sites
14
Observations
21
Career since
Apr 2010
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 Dec 2019 | Human Drugs | View 483 → |
| Duke Clinical Research Institute | 17 Jan 2019 | Human Drugs | |
| Kathryn J. Lucas, M.D. | 27 Aug 2018 | Human Drugs | View 483 → |
| Ionis Pharmaceuticals Inc. | 2 Mar 2018 | Human Drugs | |
| Novo Nordisk A/S | 10 Nov 2017 | Human Drugs |
Sites inspected
Boehringer Ingelheim Pharmaceuticals, Inc.Ridgefield, United States1 insp.
Duke Clinical Research InstituteDurham, United States1 insp.
Kathryn J. Lucas, M.D.Morehead City, United States1 insp.
Ionis Pharmaceuticals Inc.Carlsbad, United States1 insp.
Novo Nordisk A/SSoborg, Denmark1 insp.
Co-investigators
Investigators who share inspections with this person.
Brandy D Brown2 shared
Stephen T Hansen2 shared
Miah Jung1 shared
Peter R Lenahan1 shared
Lakecha N Lewis1 shared
Eileen T Monaghan1 shared
Darin S Wiegers1 shared
Rachel M Skeete1 shared
Richard W Berning1 shared
Ethan P Stegman1 shared
Full investigator report
Get the verbatim findings behind Cynthia F Kleppinger's 21 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site